共 9 条
[1]
RandomizedphaseIIstudyofBR96 doxorubicinconjugateinpatientswithmetastaticbreastcancer. TolcherAW,SugarmanS,GelmonKA,etal. JClinOncol . 1999
[2]
Antibodiesstageacomebackincancertreatment. DickmanS. Science . 1998
[3]
Selectiveablationofactivemyeloidleukemiausingantibody targetedchemotherapy :aphaseIstudyofananti CD33calicheamicinimmunoconjugate. SieversEL,AppelbaumFR,SpielbergerRT,etal. Blood . 1999
[4]
PhaseI/IItrialof ( 131) I MN 14F (ab) 2anti carcinoembryonicantigenmonoclonalantibodyinthetreatmentofpatientswithmetastaticmedullarythyroidcarcinoma. JuweidME,HajjarG,SwayneLC,etal. Cancer . 1999
[5]
Pharmacokineticsandbiodistributionof genetically engineeredantibodies. ColcherD,PavlinkovaG,BeresfordG,etal. QJNuclMed . 1998
[6]
High linearenergytransfer (LET )alphaversuslow LETbetaemittersinradioimmunotherapyofsolidtumors:therapeuticefficacyanddose limitingtoxicityof 2 13Bi versus 90Y labeledC0 17 1AFab′fragmentsinahumancoloniccancermodel. BehrTM,BeheM,StabinMG,etal. Cancer Research . 1999
[7]
6 7Cu 2IT BAT Lym 1pharmacokinetics,radiationdosimetry ,toxicityandtumorregressioninpatientswithlymphoma. DeNardoSJ,DeNardoGL,KukisDL,etal. JNuclMed . 1999
[8]
Advancesincancerimmunotherapy. OckertD,SchmitzM,HamplM,etal. Immunology Today . 1999
[9]
Experimentalstudiesontheroleofantibodyfragmentsincancerradio immunotherapy :Influenceofradiationdoseanddoserateontoxicityandanti tumorefficacy. BehrTM,MemtsoudisS,SharkeyRM,etal. International Journal of Cancer . 1998